1 August 2014 in Journal of Biomedical Nanotechnology
Resveratrol (trans-3,4',5-trihydroxystilbene, RES) is a naturally occurring lipophilic antioxidant that has been intensively studied for its promising efficacy in treating oxidative stress-associated disorders. Despite the array of bioactivities that it possesses, RES has low bioavailability due to its poor aqueous solubility and dissolution properties. Recent nanotechnology has led to the effective development of drug delivery systems. In this study, RES-loaded nanoparticles (RES-NPs) were prepared based on amphiphilic methoxy-polyethyleneglycol-poly-caprolactone (mPEG-PCL) block copolymers, which improve the physical properties of resveratrol in aqueous solution. The antioxidative capacity of RES-NPs was then evaluated sequentially in vitro and in vivo. RES-NPs exhibited stronger radical scavenging and anti-lipid peroxidization compared to that of raw RES in aqueous solution. The pre-treatment of irradiated Caenorhabditis elegans (C. elegans) with RES-NPs extended both the maximum and mean life span. Furthermore, the RES-NPs were capable of alleviating injury from gamma-ray radiation and amyloid-beta peptide overexpression toxicity in C. elegans through radical scavenging and over-regulation of SOD-3 expression. The enhancement of in vitro antioxidation properties in aqueous solution and protection against oxidative stress in C. elegans induced by both gamma-ray radiation and amyloid-beta peptide confirmed the successful development of antioxidant nanoparticles.
1 October 2020 in Neuropsychiatric Disease and Treatment
Purpose: Gait impairment is a common clinical symptom of patients with Parkinson’s disease (PD). Detecting specific gait parameters’ changes in order to guide clinical intervention is at present lacking. The present study aimed to (1) quantify gait impairments in different PD subtypes and (2) explore whether the results of quantitative gait analysis are beneficial to clinical treatment. Patients and Methods: We enrolled 86 patients with PD (48 men, and 38 women) from the Department of Geriatrics of the Affiliated Brain Hospital of Nanjing Medical University. Unified Parkinson’s Disease Rating Scale (UPDRS) and Hoehn-Yahr Scale were used to evaluate the motor symptoms of PD. All patients stopped anti-Parkinsonian medication for 24 hours (72 hours for controlled release medicine). The patients were divided into two subtypes, namely, postural instability gait difficulty (PIGD; n=56) and tremor dominant (TD; n=30) subtypes according to UPDRS. All patients completed the instrumented stand and walk test, and a set of JiBuEn gait analysis system was used in gait data collection. Results: We observed a shorter stride length (p=0.021), a longer stride time (p=0.036), a faster cadence (p=0.036), and a more variable stride length (p=0.012) in the PIGD group compared with the TD group. In addition, compared with the TD group, we found that the toe-off angle (p=0.005) and the range of motion of ankle joint (p=0.009) decreased in the PIGD group. Conclusion: Our study demonstrated that the gait performance of patients with PIGD is worse than those with TD from the perspective of quantitative gait analysis. We extended previous research and found the PIGD group exhibited severe gait impairments in some specific spatiotemporal and kinematic gait parameters. The different manifestations of these gait impairments may guide in choosing appropriate treatment of patients with different PD subtypes.
1 March 2021 in Risk Management and Healthcare Policy
Background and Purpose: Gait analysis and the effects of levodopa on the gait characteristics in Mild parkinsonian signs (MPS) are rarely published. The present research aimed to (1) analyze the gait characteristics in MPS; (2) explore the effects of levodopa on the gait performance of MPS. Methods: We enrolled 22 inpatients with MPS and 20 healthy control subjects (HC) from Nanjing Brain Hospital. The Unified Parkinson’s Disease Rating Scale was used to evaluate motor symptoms. Acute levodopa challenge test was performed to explore the effects of levodopa on the gait performance of MPS. The instrumented stand and walk test was conducted for each participant and the JiBuEn gait analysis system was used to collect gait data. Results: For spatiotemporal parameters: Compared with HC, the state before taking levodopa/benserazide in MPS group (meds-off) demonstrated a decrease in stride length (SL) (p≤ 0.001), an increase in SL variability (p≤ 0.001), and swing phase time variability (p=0.016). Compared with meds-off, the state after 1 hour of taking levodopa/benserazide in MPS group (meds-on) exhibited an increase in SL (p≤ 0.001), a decrease in SL variability (p≤ 0.001). For kinematic parameters: Compared with HC, meds-off demonstrated a decrease in heel strike angle (p=0.008), range of motion (ROM) of knee joint (p=0.011) and ROM of hip joint (p=0.007). Compared with meds-off, meds-on exhibited an increase in HS (p≤ 0.001). Bradykinesia and rigidity scores were significantly correlated with gait parameters. Conclusion: Although the clinical symptoms of the MPS group are mild, their gait damage is obvious and they exhibited a decreased SL and joints movement, and a more variable gait pattern. Levodopa had little effect on the gait performance of those individuals.
19 December 2022 in Neuropsychiatric Disease and Treatment
Objective: Patients with rapid eye movement (REM) sleep behavior disorder (RBD) in Parkinson’s disease (PD-RBD) tend to have poor cognitive performance and faster cognitive deterioration, and the potential mechanism is still ambiguous. Therefore, this study aimed to detect the alterations in local brain function in PD-RBD. Methods: Fifty patients, including 23 patients with PD-RBD and 27 patients with PD without RBD (PD-nRBD), and 26 healthy controls were enrolled. All subjects were subjected to one-night polysomnography and underwent resting-state functional magnetic resonance imaging (rs-fMRI). The fMRI images of the three groups were analyzed by regional homogeneity (ReHo) to observe the local neural activity. Correlations between altered ReHo values and chin electromyographic (EMG) density scores and cognitive scores in the PD subgroups were assessed. Results: Compared with the patients with PD-nRBD, the patients with PD-RBD had higher ReHo values in the frontal cortex (the right superior frontal gyrus, the right middle frontal gyrus and the left medial superior frontal gyrus), the right caudate nucleus and the right anterior cingulate gyrus, and compared with the HCs, the patients with PD-RBD had lower ReHo values in the bilateral cuneus, the bilateral precuneus, the left inferior temporal gyrus and the left inferior occipital gyrus. For the patients with PD-RBD, the phasic chin EMG density scores were positively correlated with the ReHo values in the left medial superior frontal gyrus, and the tonic chin EMG density scores were positively correlated with the ReHo values in the right anterior cingulate gyrus. Conclusion: This study indicates that increased ReHo in the frontal cortex, the caudate nucleus and the anterior cingulate gyrus may be linked with the abnormal motor behaviors during REM sleep and that decreased ReHo in the posterior regions may be related to the visuospatial–executive function in patients with PD-RBD.
1 May 2005 in ACC Current Journal Review
15 September 2026 in Journal of Alzheimer’s Disease
Background: Neurovascular coupling (NVC) reflects the coordination between neuronal activity and cerebral perfusion, and impaired NVC has been implicated in cognitive decline. Objective: To characterize imaging-based NVC-related measures at global and regional levels and examine their associations with polysomnography-derived sleep parameters and cognitive performance in mild cognitive impairment (MCI) and mild Alzheimer's disease (AD). Methods: Twenty-one healthy controls (HC), 21 individuals with MCI, and 22 patients with mild AD underwent arterial spin labeling, resting-state functional MRI, overnight polysomnography, and neuropsychological assessment. Global cerebral blood flow–regional homogeneity (CBF–ReHo) coupling and regional CBF/ReHo ratios were quantified as imaging-based NVC-related measures. Group comparisons, partial correlations, exploratory logistic regression models, and apnea-hypopnea index (AHI)-adjusted sensitivity analyses were performed. Results: Global CBF–ReHo coupling was significantly lower in both MCI and mild AD than in HC. Voxel-wise analyses identified lower CBF/ReHo ratios in the left inferior temporal gyrus in MCI and the right fusiform gyrus in mild AD, with the fusiform finding attenuated after AHI adjustment. N3 sleep percentage was positively associated with global CBF–ReHo coupling in mild AD and with regional CBF/ReHo ratios in group-specific ventral temporal clusters; these regional ratios were positively associated with Montreal Cognitive Assessment in MCI and Mini-Mental State Examination in mild AD. Exploratory logistic models using global CBF–ReHo coupling showed preliminary discrimination between cognitively impaired participants and HC but limited MCI–AD discrimination. Conclusions: These findings suggest a potential sleep–neurovascular link in cognitive impairment and warrant longitudinal and interventional studies to clarify the role of NVC-related imaging measures.